What is the likelihood that a 33‑year‑old woman will develop HER2‑positive, grade 3 invasive ductal carcinoma with axillary lymph‑node metastasis (stage III)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 24, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Incidence of HER2+ Stage III Grade 3 Invasive Ductal Carcinoma with Axillary Metastasis in Young Women

A 33-year-old woman faces a relatively uncommon but not rare scenario: HER2-positive invasive ductal carcinoma represents approximately 15-20% of all breast cancers, and younger age (under 40) is associated with a slightly higher prevalence of HER2-positive disease at 26.8% compared to 20.5% in women aged 40-69 years. 1

Breaking Down the Individual Risk Components

Age-Related Incidence

  • Breast cancer in women under 35 years is uncommon, though the specific scenario described represents a subset of early-onset disease 2
  • The American Cancer Society estimates approximately 55,720 new DCIS cases annually in the United States, with invasive disease being more common 3

HER2-Positive Disease Prevalence

  • HER2-positive breast cancer accounts for 15-20% of all breast cancers 1
  • Among younger women (under 40 years), HER2-positive disease occurs in approximately 26.8% of breast cancer cases, representing a higher proportion than in older age groups 1

Axillary Lymph Node Metastasis Likelihood

The presence of axillary lymph node metastasis is strongly associated with tumor characteristics rather than age alone:

  • Overall, approximately 36% of patients with invasive breast cancer have axillary lymph node metastases at diagnosis 4
  • Stage III breast cancer (which includes node-positive disease) demonstrates an 84% rate of axillary nodal metastases, with 32% having level III metastases 5

HER2-Positive Subtype and Nodal Involvement

HER2-positive tumors demonstrate specific patterns of axillary involvement:

  • HR+/HER2+ tumors have an odds ratio of 1.958 (95% CI 1.542-2.486) for nodal positivity compared to triple-negative disease 6
  • HR-/HER2+ tumors have an odds ratio of 1.525 (95% CI 1.181-1.970) for nodal positivity compared to triple-negative disease 6
  • HER2-positive status is independently associated with higher rates of axillary lymph node metastasis 6

Grade 3 Disease Impact

High-grade tumors significantly increase the likelihood of axillary involvement:

  • Grade 3 (poorly differentiated) tumors demonstrate a 37% rate of level III axillary metastases in stage III disease 5
  • Nuclear grade is an independent predictor of axillary lymph node metastases in multivariate analysis 4
  • Only 10% of well-differentiated tumors had level III metastases compared to 36-37% for moderately and poorly differentiated tumors 5

Synthesizing the Overall Probability

Combining these factors, a 33-year-old woman with the specific constellation of HER2-positive, grade 3 invasive ductal carcinoma with stage III disease (indicating lymph node involvement) represents approximately 4-6% of all breast cancer cases in this age group:

  • Young age (under 40): represents minority of breast cancer cases
  • HER2-positive: 26.8% of breast cancers in this age group 1
  • Grade 3: approximately 30-40% of invasive ductal carcinomas
  • Node-positive disease: 36% overall, but higher (60-84%) in stage III presentations 4, 5

Important Clinical Context

This specific presentation, while representing a minority of breast cancer cases, is well-recognized and has established treatment protocols:

  • Neoadjuvant chemotherapy plus pertuzumab-trastuzumab is standard of care for HER2-positive disease with tumors ≥2 cm and/or node-positive disease 7
  • The 8-year overall survival rate for HER2-positive metastatic disease treated with dual HER2 blockade (trastuzumab, pertuzumab, and docetaxel) is 37%, demonstrating the impact of modern HER2-targeted therapy 1
  • Young age itself does not alter the indication for standard HER2-targeted therapy, which includes one year of adjuvant trastuzumab for HER2-positive, node-positive disease 2

Prognostic Considerations

Despite the aggressive features (young age, grade 3, node-positive), HER2-positive disease has dramatically improved outcomes with modern therapy:

  • The 12-year overall survival rate with adjuvant trastuzumab in HER2-positive early breast cancer is 79% versus 73% without trastuzumab 1
  • Patients with HER2-positive disease presenting with clinical node-positive tumors or those measuring ≥2 cm should receive therapy incorporating HER2-targeted agents 8

References

3
Guideline

acr appropriateness criteria® imaging of ductal carcinoma in situ (dcis).

Journal of the American College of Radiology, 2025

8
Guideline

breast cancer, version 3.2024, nccn clinical practice guidelines in oncology.

Journal of the National Comprehensive Cancer Network : JNCCN, 2024

Related Questions

In a patient who is two months pregnant and diagnosed with stage IIIB breast cancer, should she terminate the pregnancy to allow optimal cancer treatment?
What are the treatment options for a 40-year-old female with breast cancer?
For a 45-year-old premenopausal woman with a 1.8 cm grade 1 hormone‑receptor‑positive, HER2‑negative, node‑negative invasive ductal carcinoma and a Recurrence Score of 18, is four cycles of adjuvant docetaxel‑cyclophosphamide (TC) the appropriate chemotherapy regimen?
What is the appropriate urgent evaluation and management for a 48-year-old woman with breast cancer who presents with prolonged heavy irregular vaginal bleeding causing dizziness?
Does a 2.6 cm invasive breast cancer automatically require a mastectomy?
What is driving pressure during mechanical ventilation, and what target value should be maintained and how can it be optimized?
Why is this 54‑year‑old overweight male with hypertension, atherogenic dyslipidemia, elevated random blood glucose, massive glucosuria, mild proteinuria, and normal thyroid function diagnosed with type 2 diabetes mellitus?
What are the landmark clinical trials that guide the resumption of antiplatelet and anticoagulant therapy after stroke?
Is ropinirole safe in a patient with supraventricular tachycardia?
What is the recommended initial treatment plan for a 54‑year‑old male real‑estate agent with hypertension, obesity, hyperglycemia, dyslipidemia, and early diabetic nephropathy?
What is the appropriate ciprofloxacin (Cipro) dosing regimen for an adult with a Klebsiella infection, including adjustments for severe infection and impaired renal function?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.